A Survey of the FDA’s Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter‐2 Inhibitor Use
Sign Up to like & getrecommendations! Published in 2019 at "Diabetes Therapy"
DOI: 10.1007/s13300-019-0611-9
Abstract: IntroductionWe tested the possible association between sodium glucose cotransporter-2 inhibitor (SGLT-2i) use and urogenital tract infection (UTI) occurrences by assessing the publicly available US Food and Drug Administration Adverse Event Reporting System (FAERS).MethodsDisproportionality analysis and… read more here.
Keywords: adverse event; sodium glucose; use; urogenital tract ... See more keywords
Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15348
Abstract: DWP16001 is a novel sodium–glucose cotransporter‐2 inhibitor under development for the treatment of type 2 diabetes mellitus. This study was conducted to evaluate the pharmacokinetics, pharmacodynamics and safety of DWP16001 after single and multiple doses… read more here.
Keywords: cotransporter inhibitor; glucose cotransporter; dwp16001; dwp16001 novel ... See more keywords
Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium–glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15632
Abstract: DWP16001, a novel sodium–glucose cotransporter 2 inhibitor, is under clinical development for the treatment of type 2 diabetes mellitus. This study aimed to explore the pharmacokinetics (PK) and pharmacodynamics interaction of DWP16001 with gemigliptin and… read more here.
Keywords: cotransporter inhibitor; glucose cotransporter; gemigliptin metformin; dwp16001 ... See more keywords
Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium–glucose cotransporter 2 inhibitor: A randomized, open‐label, prospective study
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Diabetes Investigation"
DOI: 10.1111/jdi.12994
Abstract: Hyperglycemia impairs energy substrate oxidation as a result of glucotoxicity. We examined whether the reduction of plasma glucose using a sodium–glucose cotransporter 2 inhibitor, in inpatient diabetes management, has any effect on: (i) treatment period… read more here.
Keywords: cotransporter inhibitor; glucose cotransporter; sodium glucose; oxidation ... See more keywords
When Guidelines Fail: Euglycemic Diabetic Ketoacidosis After Bariatric Surgery in a Patient Taking a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report.
Sign Up to like & getrecommendations! Published in 2018 at "A&A Practice"
DOI: 10.1213/xaa.0000000000000734
Abstract: A 42-year-old woman with diabetes mellitus type 2 treated with the sodium-glucose cotransporter-2 inhibitor canagliflozin underwent elective bariatric gastric bypass. The canagliflozin was held for 24 hours preoperatively. She physiologically decompensated on postoperative day 2.… read more here.
Keywords: cotransporter inhibitor; glucose cotransporter; sodium glucose;
Sodium-Glucose Cotransporter-2 Inhibitor versus Beta-Blocker Use for Hepatocellular Carcinoma Risk among People with Hepatitis B or C Virus Infection and Diabetes Mellitus
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15072104
Abstract: Simple Summary The authors used a large Taiwanese database of patients with chronic hepatitis B or C in order to study if SGLT2I, as compared to BB, may decrease HCC. In brief, SGLT2I caused a… read more here.
Keywords: versus beta; hcc; cotransporter inhibitor; glucose cotransporter ... See more keywords